We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1) (PAGE-1_AG1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01426516
Recruitment Status : Terminated (Invalid data collection)
First Posted : August 31, 2011
Results First Posted : November 30, 2015
Last Update Posted : November 30, 2015
Information provided by (Responsible Party):
Genomind, LLC

Brief Summary:

One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials. Such treatment-resistant depression (TRD) contributes disproportionately to the tremendous costs of MDD, in terms of health care costs, functional impairment, and diminished quality of life.

The promise of personalized medicine for individuals at high risk for TRD is apparent. If these individuals could be recognized early in their disease course, they could be triaged to more intensive or targeted interventions to improve their likelihood of remission. With the proliferation of treatment options in MDD, at present individuals can spend months or years in and out of treatment before receiving these next-step treatments.

At present, no clinical or biomarker-based tool has been shown to assist in matching patients with treatments most likely to be effective for them. The Genecept Assay offers the possibility of "Personalized Medicine" in psychiatry. Clinicians may find this additional genetic information can lead to optimized treatment plans for individual patients. Before such an assay can be widely applied clinically, it is necessary to demonstrate that this tool usefully impacts treatment outcomes.

This study will examine the potential impact of the assay in terms of depression severity at 3 months, with further follow-up out to 6 months. Secondary measures will allow an estimate of its potential to change clinician behavior and improve patient quality of life. Further measures will also allow for refinement of the assay to maximize patient and clinician satisfaction, and estimate the potential savings associated with deployment of this assay in real-world clinical settings.

Condition or disease Intervention/treatment
Major Depressive Disorder Device: Genecept Assay

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Official Title: A Six-month Study of the Genecept Assay vs. Treatment as Usual to Evaluate Efficacy of Using Assay Guided Treatment in Outpatient Adults With Treatment Resistant Depression
Study Start Date : September 2011
Primary Completion Date : June 2014
Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Genetic Testing
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Treatment as usual (TAU)
Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
Experimental: Genecept Assay
Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
Device: Genecept Assay
Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
Other Name: Genetic Test

Primary Outcome Measures :
  1. Efficacy Measured by Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), Adjusted for Baseline Severity, at 6 Months [ Time Frame: 6 months ]

    To determine the efficacy of assay-guided treatment (AGT) versus treatment-as-usual (TAU), in terms of depression severity as measured by change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), adjusted for baseline severity, at 6 months


    • highest score on any 1 of the 4 sleep items (items 1 to 4)
    • highest score on any 1 of the 4 weight items (items 6 to 9)
    • highest score on either of the 2 psychomotor items (15 and 16)
    • scores for each of the 6 MDD symptom domains

    Total scores range from 0-27. 0 = no signs of depression; 27 = severe depression

Secondary Outcome Measures :
  1. Clinician Behavior as Measured by Change in Recorded Treatment Choice Before and After the Assay Results Are Made Available. [ Time Frame: one week ]
    Clinicians will rank first and alternative treatment choice and dosage prior to assay and first and two alternative treatment choices after receiving assay results (for AGT group). Clinician choices will be compared.

  2. Quality of Life as Measured by Self Reported Assessment of Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) [ Time Frame: baseline, 3, 6 months ]
    To determine the efficacy of assay-guided treatment (AGT) versus treatment-as-usual (TAU) in outpatient treatment of nonpsychotic major depressive disorder, in terms of patient quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)) The minimum raw score on the QLESQ is 14, and the maximum score is 70.

  3. Cost [ Time Frame: 6 months ]
    To compare costs of AGT versus TAU in outpatient treatment of nonpsychotic major depressive disorder as measured by claims data.

  4. Acceptability of the Use of AGT for Subjects and Clinicians as Measured by Satisfaction Survey [ Time Frame: 6 months ]
    To determine the acceptability to patients and clinicians of assay-guided treatment (AGT) versus treatment-as-usual (TAU) in outpatient treatment of nonpsychotic major depressive disorder

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 18-65
  • written informed consent
  • diagnosis of non-psychotic major depression as determined by study
  • clinician/current medical prescriber, and mood disorder diagnosis confirmed by PHQ-9
  • QIDS-SR score of at least 10 (i.e., moderate depression) at initial visit
  • failure of at least 1 prior adequate trial of a standard antidepressant (by ATRQ criteria - i.e., 6 weeks at adequate dose)

Exclusion Criteria:

  • psychotic features in the current episode, based upon clinical assessment
  • 4 or more failed pharmacologic interventions in the current major depressive episode [response rates for these subjects is likely to be extremely low and would require a substantially larger-scale study to identify treatment effects]
  • current substance use disorder other than nicotine which based upon clinical assessment requires inpatient or outpatient detoxification
  • pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)
  • women who are breastfeeding
  • serious suicide or homicide risk, as assessed by evaluating clinician
  • other unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease, based on review of medical history, physical examination, and screening laboratory tests
  • patients who have taken an investigational psychotropic drug within the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426516

United States, Tennessee
Nashville, Tennessee, United States, 37228
Sponsors and Collaborators
Genomind, LLC
Study Director: Rachel Dicker, PharmD Genomind, LLC

Responsible Party: Genomind, LLC
ClinicalTrials.gov Identifier: NCT01426516     History of Changes
Other Study ID Numbers: AG1-0001/2
First Posted: August 31, 2011    Key Record Dates
Results First Posted: November 30, 2015
Last Update Posted: November 30, 2015
Last Verified: October 2015

Keywords provided by Genomind, LLC:
Treatment Resistant

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms